Vaxart Appoints Biotech Veteran Dr. James Breitmeyer to Board of Directors

summarizeSummary

Vaxart appointed Dr. James Breitmeyer, a highly experienced biopharmaceutical executive, to its Board of Directors, bolstering its clinical development and regulatory expertise.

check_boxKey Events

• New Board Member Appointed

  Dr. James B. Breitmeyer, M.D., Ph.D., was appointed to the Board of Directors, effective April 23, 2026.

• Extensive Industry Experience

  Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including CEO roles at Altay Therapeutics and Oncternal Therapeutics, and senior positions at Bavarian Nordic, Eli Lilly, and Cadence Pharmaceuticals, with a track record of eight FDA product approvals.

• Strengthens Clinical and Regulatory Expertise

  His appointment is expected to enhance the Board's capabilities in clinical development and regulatory strategy, crucial for Vaxart's oral vaccine platform, especially given the company's recent financial and strategic challenges.

auto_awesomeAnalysis

The appointment of Dr. James Breitmeyer, a seasoned biopharmaceutical executive with over 35 years of experience in clinical development and regulatory approvals, strengthens Vaxart's Board of Directors. His expertise is particularly valuable for a clinical-stage company like Vaxart, especially as it navigates recent financial challenges and strategic adjustments, including a going concern warning and recent capital raises. This move enhances the company's leadership and strategic capabilities.